b. detecting the presence of human iNOS protein in said sample, said particular binding monoclonal antibody recognizing human iNOS protein.

83(previously added claim 63, currently amended): A binding assay method for analysis of a sample, comprising the steps of:

a. contacting the sample with a particular binding entity specifically reactive to human iNOS, said particular binding entity selected from the group consisting essentially of an oligonucleotide, a polymer mimicking an artificial antibody, and a phage displayed binding site; and

b. detecting the presence of human iNOS protein in said sample, said particular binding entity specifically recognizing human iNOS protein.

84(formerly claim 64): The method of claim 82 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

85(formerly claim 65, currently amended): The method of claim 83 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26) NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29),

PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

86(formerly claim 66, newly amended): The method of claim 82 in which said immunoassay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

87(formerly claim 67): The method of claim 82 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

88(formerly claim 68): The method of claim 82 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

89(new): The method of claim 83 in which said binding assay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

90(new): The method of claim 82 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

91(new): The method of claim 82 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

92 (formerly claim 69, newly amended): A binding assay method for a sample,

comprising the steps of:

a. contacting the sample with a specific binding entity reactive to a mimic of human iNOS protein without cross-reacting

with human nNOS protein or human eNOS protein; and

b. detecting the presence of human iNOS protein in said sample, said specific binding entity recognizing mimics of human iNOS protein.

93(formerly claim 70): The method of claim 92 in which said mimic of human iNOS protein is selected from the group consisting essentially of: peptides, recombinant peptides, fusion proteins, fusion peptides, phage displayed proteins, phage displayed peptides, peptide libraries, and peptide analogue libraries.

94(New): The method of claim 92 in which said specific binding entity is selected from the group consisting essentially of:

a monoclonal antibody, an oligonucleotide, a polymer mimicking an artificial antibody, and a phage displayed binding site.

95(formerly claim 71, newly amended): The method of claim 89 in which said region of human iNOS protein is selected from the group consisting essentially of the sequences: NNNVEKAPCATSSPVTQD (SEQ ID NO 32), SPVTQDDLQYHNLSKQQN (SEQ ID NO 26), NNNVEKAPCATSSPVTQD plus SPVTQDDLQYHNLSKQQN (SEQ ID NO 29), PALVQGILERVVDGPTPH (SEQ ID NO 30), GIVPFRSFWQQRLHDSQH (SEQ ID NO 25), and RMTLVFGSRRPDEDHITQ (SEQ ID NO 31).

96(formerly claim 72): The method of claim 92 in which said binding assay is selected from the group comprising: direct, indirect, capture, competitive binding, and displacement.

97(formerly claim 73): The method of claim 92 in which said binding assay comprises a clinical diagnostic assay.

98(formerly claim 74): The method of claim 92 in which said step of detecting the presence of human iNOS protein comprises a qualitative analysis.

99(formerly claim 75): The method of claim 92 in which said step of detecting the presence of human iNOS comprises a quantitative analysis.

100(formerly claim 76): The method of claim 92 in which said specific binding entity comprises any one of the peptide analogues of Table VII.

101(formerly claim 77): The method of claim 92 in which said specific binding entity comprises any one of the peptide analogues of Table IX.

102(formerly claim 78): The method of claim 92 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

103(formerly claim 79): The method of claim 82 which is of the type selected from the group consisting essentially of: IFA, linear flow, radial flow, Western Blot, ELISA, dip stick, EIA, fluorescent polarization, enzyme capture, and RIA.

104(formerly claim 88): The method of claim 100 in which said specific binding entity is a peptide analogue having the sequence: VTQDDLQ (SEQ ID NO 89).

105(formerly claim 81): The method of claim 101 in which said specific binding entity is a peptide analogue having the sequence: VQGILERV (SEQ ID NO 120).

106(new): A binding assay for iNOS contained in a sample comprising:

a. a specific binding entity reactive to human iNOS; and

b. a vehicle for revealing the presence of human iNOS according to said specific binding entity recognizing a region of human iNOS protein.